Shanghai Henlius Biotech Initiates International Phase 1 Clinical Study of Pembrolizumab Biosimilar HLX17
Shanghai Henlius Biotech, Inc. (Stock code: 2696) has announced a significant development in its oncology pipeline: the first patient has been dosed in an international, multi-center Phase 1 clinical study evaluating HLX17, a biosimilar of pembrolizumab (recombinant humanized anti-PD-1 monoclonal antibody injection). This marks a major milestone in the company’s efforts to enter the global immuno-oncology market.
Key Highlights for Investors
- First Patient Dosed: The study has commenced with the first patient dosed in the United States, with simultaneous trials ongoing in Mainland China.
- HLX17 – Pembrolizumab Biosimilar: HLX17 is independently developed by Henlius and targets a broad range of solid tumours, mirroring the indications of the reference drug, Keytruda®.
- Study Design: The trial is a multicenter, randomized, double-blind, parallel-controlled Phase 1 study. It compares the pharmacokinetics (PK), efficacy, safety, and immunogenicity of HLX17 with US-sourced Keytruda® in patients with multiple resected solid tumours, including non-small cell lung cancer, melanoma, and renal cell carcinoma.
- Randomization and Treatment Arms: Participants are randomized 1:1 to receive either HLX17 or Keytruda® (200 mg, Q3W). After 8 cycles, the Keytruda® arm switches to HLX17, with both arms continuing treatment up to 12 months or until disease progression, death, or other discontinuation criteria are met.
- Primary Endpoints: The main objectives are to demonstrate PK similarity (AUC0-21d after the 1st dose and AUCss after the 6th dose). Secondary endpoints include additional PK parameters, efficacy, safety, and immunogenicity.
- Regulatory Progress: HLX17 received clinical trial approval from China NMPA in September 2024 and IND clearance from the US FDA in September 2025. The first patient in China was dosed in September 2025.
- Market Opportunity: Global sales of pembrolizumab reached approximately USD 35.423 billion in 2025, highlighting a significant commercial opportunity for HLX17 if successful.
Strategic and Potential Share Price Impacts
This update is potentially price sensitive for several reasons:
- Global Expansion: HLX17 is being trialed both in China and the US, indicating Henlius’ ambitions to capture a share of the global immuno-oncology market, which is currently dominated by Merck’s Keytruda®.
- Large Market Potential: With pembrolizumab’s global sales exceeding \$35 billion, a successful biosimilar could generate substantial revenue and positively impact Henlius’ valuation.
- Pipeline Validation: Progression to international Phase 1 trials signals regulatory confidence in Henlius’ R&D capabilities and may strengthen investor sentiment about the company’s pipeline quality.
Risks and Cautionary Statement
Despite these positive developments, shareholders should note:
- Development Risk: There is no guarantee HLX17 will successfully complete clinical development or achieve commercialization.
- Regulatory and Competitive Risks: The biosimilar market is highly competitive, and regulatory outcomes are uncertain.
Investors are advised to exercise caution when dealing in the shares of Shanghai Henlius Biotech, Inc., as clinical development outcomes are inherently uncertain and can significantly affect share price performance.
Disclaimer
The information contained in this article is for informational purposes only and does not constitute investment advice. Investors should consider their own circumstances and consult with their professional advisors before making investment decisions. The company cannot guarantee the successful development or commercialization of HLX17.
上海復宏漢霖生物技術國際多中心HLX17帕博利珠單抗生物類似藥一/一期臨床試驗首例患者用藥
上海復宏漢霖生物技術有限公司（股份代號：2696）發佈重大業務進展：公司自主研發的HLX17（帕博利珠單抗生物類似藥，重組人源化抗PD-1單克隆抗體注射液）於國際多中心I期臨床試驗中，已於美國完成首例患者用藥，並在中國內地同步開展。
投資者重點信息
- 首例患者用藥： 標誌著HLX17國際臨床試驗正式啟動，涵蓋美國及中國內地。
- HLX17產品背景： HLX17為帕博利珠單抗(Keytruda®)生物類似藥，潛在適應症包括多種惡性腫瘤，與原研藥一致。
- 臨床設計： 為多中心、隨機、雙盲、平行對照I期臨床，對比HLX17與美國來源Keytruda®在多種已切除實體瘤（如非小細胞肺癌、黑色素瘤、腎細胞癌）患者的藥代動力學(PK)、療效、安全性及免疫原性。
- 隨機分組及治療： 受試者按1:1隨機分至HLX17或Keytruda®組，兩組均靜脈輸注200mg每三週一次。Keytruda®組用藥8周期後轉至HLX17，總治療周期最多12個月，或至疾病復發、死亡、不良反應或其他終止條件為止。
- 主要終點： 以首劑後21天及第6劑達穩態時的AUC（血清濃度-時間曲線下面積）評估PK相似性。次要終點包括其他PK指標、療效、安全性和免疫原性。
- 監管進展： 2024年9月獲中國NMPA臨床批件，2025年9月獲美國FDA一/一期臨床IND批准，並於同月在中國內地完成首例患者給藥。
- 市場機會： 據IQVIA，2025年帕博利珠單抗全球銷售額約354.23億美元，若HLX17商業化成功，潛在收益巨大。
潛在股價影響及注意事項
此消息具有潛在敏感性，可能影響股價，原因包括：
- 國際化步伐： 同步在中國與美國開展臨床，顯示公司爭取全球市場決心。
- 龐大市場份額： 若HLX17能順利上市，有望佔據部分Keytruda®巨大市場份額，提升公司估值。
- 管線價值驗證： 項目進展顯示研發能力獲監管機構認可，或提升市場信心。
風險提示
需注意事項包括：
- 開發風險： HLX17能否成功開發及商業化，尚無保證。
- 監管及競爭風險： 生物類似藥市場競爭激烈，監管審批具不確定性。
投資者應審慎評估本公司股票，因為臨床開發存在不確定性，結果將直接影響股價表現。
免責聲明
本文僅供參考，並不構成投資建議。投資者需根據自身情況，諮詢專業人士後再作決定。本公司不能保證HLX17順利開發及商業化。
